Oxyntomodulin-based therapy for lowering cholesterol, and triglycerides levels: Oxyntomodulin (OXM), a 37 amino acid intestinal peptide that  inhibits food intake and body weight, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 29/April/2019, 2.58 pm

Caloric restriction restricts perception of pain: Mechanistic insights into how caloric restriction functions as a pain medication:  Caloric restriction increases the expression of PD-L1, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 29/April/2019, 2.47 pm
April 29, 2019
Neuropeptide Y-based therapy for inflammation and arthritis: Neuropeptide Y, a  36 amino-acid neuropeptide that plays a role in the regulation of food intake, storage of food, anxiety, stress, perception of pain and others, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 29/April/2019, 3.10 pm
April 29, 2019
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests an Oxyntomodulin (OXM)-based therapy for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD). Oxyntomodulin (OXM), by increasing the expression of its rtrget gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, a pharmaceutical formulations encompassing Oxyntomodulin (OXM) or its activators, either alone or in combination with other drugs, may be used to treat NAFLD (Fig.2).

Figure 1. Mechanistic insights into how Oxyntomodulin (OXM) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD

Figure 2.  Oxyntomodulin (OXM)  functions as a cholesterol-lowering agent. Oxyntomodulin (OXM) lowers cholesterol and triglyceride levels and attenuates NAFLD, through down-regulation of HMGCR

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does oxyntomodulin (OXM) decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Oxyntomodulin-based therapy for lowering cholesterol, and triglycerides levels: Oxyntomodulin (OXM), a 37 amino acid intestinal peptide that  inhibits food intake and body weight, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 29/April/2019, 2.58 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.